[1] ADMINISTRATION U F A D. FDA report: background package for NDA 21-356: VIREAD[EB/OL]. [2018-06-10]. http:// www.fda.gov/cder/approval/v.htm.
[2] SCHERZER R, ESTRELLA M, LI Y, et al.Association of tenofovir exposure with kidney disease risk in HIV infection[J]. AIDS, 2012,26(7):867-875.
[3] MIZUSHIMA D, TANUMA J, KANAYA F, et al.WHO antiretroviral therapy guidelines 2010 and impact of tenofovir on chronic kidney disease in Vietnamese HIV-infected patients[J]. PLoS One, 2013,8(11):e79885.
[4] CHIKWAPULO B, NGWIRA B, SAGNO J B, et al.Renal outcomes in patients initiated on tenofovirdisoproxilfumarate-based antiretroviral therapy at a community health centre in Malawi[J]. Int J STD AIDS, 2018,29(7):650-657.
[5] 曹颖, 李太生. 替诺福韦相关肾毒性在人类免疫缺陷病毒感染者中的研究进展[J]. 中华医学杂志, 2013(9):709-712.
[6] MOCROFT A, LUNDGREN J, ROSS M, et al.Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study[J]. Lancet HIV, 2016,3(1):23-32.
[7] TAKANO M, TANUMA J, TSUKADA K, et al.Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study[J]. Journal of Infection and Chemotherapy, 2013,19(5):850-857.
[8] NORDEN A G, SCHEINMAN S J, DESCHODT-LANCKMAN M M, et al. Tubular proteinuria defined by a study of Dent's (CLCN5 mutation) and other tubular diseases[J]. Kidney Int, 2000,57(1):240-249.
[9] CHAN L, ASRIEL B, EATON E F, et al.Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug[J]. CurrOpinNephrolHypertens, 2018,27(2):102-112.
[10] JOTWANI V, SCHERZER R, ESTRELLA M M, et al.HIV Infection, Tenofovir, and Urine α 1 -Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study[J]. American Journal of Kidney Diseases, 2016,68(4):571-581.
[11] JAB ONOWSKA E, WÓJCIK K, PIEKARSKA A. Urine Liver-Type Fatty Acid-Binding Protein and Kidney Injury Molecule-1 in HIV-Infected Patients Receiving Combined Antiretroviral Treatment Based on Tenofovir[J]. AIDS Research and Human Retroviruses, 2014,30(4):363-369.
[12] HALL A M, EDWARDS S G, LAPSLEY M, et al.Subclinical Tubular Injury in HIV-Infected Individuals on Antiretroviral Therapy: A Cross-sectional Analysis[J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2009,54(6):1034-1042.
[13] ALOY B, TAZI I, BAGNIS C I, et al.Is TenofovirAlafenamide Safer than TenofovirDisoproxilFumarate for the Kidneys?[J]. AIDS Rev, 2016,18(4):184-192.
[14] POZNIAK A, ARRIBAS J R, GATHE J, et al.Switching to TenofovirAlafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study[J]. J Acquir Immune DeficSyndr, 2016,71(5):530-537.
[15] SAX P E, WOHL D, YIN M T, et al.Tenofoviralafenamide versus tenofovirdisoproxilfumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials[J]. Lancet, 2015,385(9987):2606-2615.
[16] NOVICK T K, CHOI M J, ROSENBERG A Z, et al.Tenofovira lafenamide nephrotoxicity in an HIV-positive patient A case report[J]. MEDICINE, 2017, 96(36):e8046.
[17] ABRAHAM P, RAMAMOORTHY H, ISAAC B.Depletion of the cellular antioxidant system contributes to tenofovirdisoproxilfumarate - induced mitochondrial damage and increased oxido-nitrosative stress in the kidney[J]. J Biomed Sci, 2013,20:61.
[18] JAFARI A, KHALILI H, DASHTI-KHAVIDAKI S.Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention[J]. European Journal of Clinical Pharmacology, 2014,70(9):1029-1040.
[19] LIBORIO A B, ANDRADE L, PEREIRA L V, et al.Rosiglitazone reverses tenofovir-induced nephrotoxicity[J]. Kidney Int, 2008,74(7):910-918.
[20] ADARAMOYE O A, ADEWUMI O M, ADESANOYE O A, et al.Effect of tenofovir, an antiretroviral drug, on hepatic and renal functional indices of Wistar rats: protective role of vitamin E[J]. J Basic ClinPhysiolPharmacol, 2012,23(2):69-75. |
